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Abstract
Mitochondria abnormalities in skeletal muscle may contribute to frailty and
sarcopenia, commonly present in patients with chronic kidney disease (CKD).
Dysfunctional mitochondria are also a major source of oxidative stress and
may contribute to cardiovascular disease in CKD. We tested the hypothesis
that mitochondrial structure and function worsens with the severity of CKD.
Mitochondrial volume density, mitochondrial DNA (mtDNA) copy number,
BNIP3, and PGC1a protein expression were evaluated in skeletal muscle biop-
sies obtained from 27 subjects (17 controls and 10 with CKD stage 5 on
hemodialysis). We also measured mtDNA copy number in peripheral blood
mononuclear cells (PBMCs), plasma isofurans, and plasma F2-isoprostanes in
208 subjects divided into three groups: non-CKD (eGFR>60 mL/min), CKD
stage 3–4 (eGFR 60–15 mL/min), and CKD stage 5 (on hemodialysis). Muscle
biopsies from patients with CKD stage 5 revealed lower mitochondrial volume
density, lower mtDNA copy number, and higher BNIP3 content than controls.
mtDNA copy number in PBMCs was decreased with increasing severity of
CKD: non-CKD (6.48, 95% CI 4.49–8.46), CKD stage 3–4 (3.30, 95% CI
0.85–5.75, P = 0.048 vs. non-CKD), and CKD stage 5 (1.93, 95% CI 0.27–
3.59, P = 0.001 vs. non-CKD). Isofurans were higher in patients with CKD
stage 5 (median 59.21 pg/mL, IQR 41.76–95.36) compared to patients with
non-CKD (median 49.95 pg/mL, IQR 27.88–83.46, P = 0.001), whereas F2-
isoprostanes did not differ among groups. Severity of CKD is associated with
mitochondrial dysfunction and markers of oxidative stress. Mitochondrial
abnormalities, which are common in skeletal muscle from patients with CKD
stage 5, may explain the muscle dysfunction associated with frailty and sar-
copenia in CKD. Further studies are required to evaluate mitochondrial func-
tion in vivo in patients with different CKD stages.
Introduction
Frailty and sarcopenia are commonly present in patients
with CKD and they are associated with increased morbid-
ity and mortality in this population (Bao et al. 2012; Iso-
yama et al. 2014). Frailty is a phenotype that requires the
presence of at least three of the following characteristics:
unintentional weight loss, self-reported exhaustion or fati-
gue, measured muscle weakness, slow walking speed, or
low physical activity (Morley et al. 2013). Approximately
73% percent of patients are frail at the time of initiation
of dialysis (Bao et al. 2012). Sarcopenia, defined as
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reduction in muscle mass or reduced muscle strength/
physical performance (Cooper et al. 2012), is one of the
components of the frailty phenotype and it is also associ-
ated with increased mortality in patients with end-stage
renal disease (Isoyama et al. 2014).
Cardiovascular morbidity and mortality is also higher
in patients with CKD compared to the general population
(Foley et al. 1998; Sarnak and Levey 1999). The probabil-
ity of cardiovascular events increases dramatically when
the estimated glomerular filtration rate (eGFR) is lower
than 45 mL/min/1.73 m2 (Go et al. 2004). Traditional
risk factors such as high cholesterol or smoking do not
explain the increased cardiovascular morbidity in CKD.
Rather, increased oxidative stress and systemic inflamma-
tion, which are present in CKD, have been proposed as
additional risk factors for cardiovascular events in patients
with CKD (Himmelfarb et al. 2002).
Mitochondria abnormalities in skeletal muscle may
explain the frailty and sarcopenia observed in CKD. Pre-
vious studies have shown that patients with CKD exhibit
skeletal muscle mitochondrial dysfunction compared to
healthy individuals (Durozard et al. 1993; Thompson
et al. 1993; Conjard et al. 1995; Pastoris et al. 1997;
Kemp et al. 2004). Briefly, these studies showed decreased
activity of mitochondrial enzymes, such as citrate synthase
and hydroxyacyl-CoA dehydrogenase, and the prolonga-
tion of phosphocreatine recovery time after exercise in
skeletal muscle in patients with CKD. A recent study in
mice also suggested that reduction in skeletal muscle
mitochondria number would precede the onset of sar-
copenia (Tamaki et al. 2014); however, no study has mea-
sured mitochondrial number in human skeletal muscle
from patients with CKD.
Mitochondrial dysfunction is associated with increased
oxidative stress and inflammation (Ide et al. 2001; Lopez-
Armada et al. 2013). Several studies have shown an asso-
ciation between mitochondrial dysfunction and
atherosclerosis (Ballinger et al. 2002; Madamanchi and
Runge 2007), suggesting that impaired mitochondrial
function may also contribute to the pathogenesis of car-
diovascular diseases. While earlier studies showed mito-
chondrial abnormalities in peripheral blood mononuclear
cells (PBMCs) from patients with CKD (Granata et al.
2009; Rao et al. 2009), no study has extensively examined
the association among the severity of CKD, mitochondrial
function, and oxidative stress.
Thus, we examined vastus lateralis muscle biopsies
from patients with CKD stage 5 undergoing maintenance
hemodialysis (MHD) for the presence of ultrastructural
and mitochondrial abnormalities using electron micro-
scopy. We tested the hypothesis that mitochondrial vol-
ume density (i.e., mitochondrial number) decreases in
skeletal muscle from patients with CKD. We also tested
the hypothesis that mitochondrial function decreases with
the severity of CKD. To this end, we measured mitochon-
drial DNA (mtDNA) copy number from PBMCs, lactate
concentrations, and the ratio of plasma isofurans to F2-
isoprostanes in patients at different stages of CKD. We
used isofurans as biomarker of oxidative stress associated
with mitochondrial function because previous studies
have shown that isofurans formation is favored over F2-
isoprostanes formation when oxygen tissue tension is
high, as observed in the setting of mitochondrial dysfunc-
tion (Fessel et al. 2002). Using an animal model of mito-
chondrial lipid peroxidation we also verified that the
induction of mitochondrial dysfunction increases the pro-
duction of isofurans relative to F2-isoprostanes.
Subjects and Methods
Subjects
Skeletal muscle biopsy group
Skeletal muscle biopsies for analysis of mitochondrial
ultrastructure by electron microscopy were obtained from
11 patients with CKD stage 5 on MHD and 17 controls.
Patients with CKD were clinically stable and had been
dialyzed three times per week for four hours at the time
of enrollment. Control subjects had normal kidney func-
tion at the time of enrollment and had similar self-
reported activity and age compared to the patients with
CKD.
Severity of CKD group
Blood samples for isolation of PBMCs and measurement
of isofurans and F2-isoprostanes were obtained from par-
ticipants in a clinical trial of patients on MHD
(NCT00878969) and a trial of subjects undergoing cardiac
surgery (NCT00791648). All measurements on the sub-
jects scheduled for elective cardiac surgery were per-
formed prior to surgery. These subjects were stable and
not experiencing acute changes in renal function or meta-
bolic homeostasis. Blood was obtained from 208 patients:
109 subjects with eGFR > 60 mL/min/1.73 m2 (non-
CKD), 36 subjects with eGFR between 60 and 15 mL/
min/1.73 m2 (CKD 3–4), and 63 subjects with
eGFR < 15 mL/min/1.73 m2 on MHD (CKD 5/MHD).
Glomerular filtration rate was estimated using the Modifi-
cation of Diet in Renal Disease (MDRD) formula. All the
subjects on hemodialysis were clinically stable and had
been dialyzed three times per week for four hours and
were on MHD for at least 6 months.
All the studies were approved by the Vanderbilt
University Institutional Review Board for Research on
2016 | Vol. 4 | Iss. 9 | e12780
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Human Subjects, and all subjects provided written
informed consent.
Muscle biopsies
Biopsies were obtained from the vastus lateralis skeletal
muscle. The biopsies from controls with normal kidney
function or from patients with CKD stage 5 on MHD
were obtained under aseptic conditions and local lido-
caine anesthesia in the Clinical Research Center (CRC) at
Vanderbilt or at the University of Kentucky CRC by per-
cutaneous needle biopsy. After removing subcutaneous
fat, biopsies were immersed in fixatives for electron
microscopy. Muscle biopsies from patients with CKD
stage 5 were obtained on a nondialysis day.
Transmission electron microscopy
Muscle biopsies were dissected and cut into small pieces
and fixed in glutaraldehyde (4%) and paraformaldehyde
(2%) for 2 h at room temperature. Samples were prepared
for electron microscopy as previously described (Gamboa
and Andrade 2012). Briefly, samples were postfixed in
osmium tetraoxide (1%) for 1 h, dehydrated and embed-
ded for further sectioning. Thin (80 nm) fiber transverse
sections were stained with uranyl acetate and lead citrate
and examined with a transmission electron microscope.
Mitochondrial volume density
Approximately 40 thin sections per subject were used for
the calculation of mitochondrial volume density in skele-
tal muscle using the stereological point counting method
as previously described (Broskey 2013). A 20 9 20 grid
(corresponding to 0.25 lm2) was superimposed on elec-
tron-micrographs captured at 11,000 magnification. Mito-
chondrial volume was calculated as the percentage of
points of the grid that intersect any mitochondria.
Western blot analysis
Skeletal muscle samples were homogenized in the presence
of proteases inhibitors and heated at 95°C with denaturing
Laemli buffer. Samples (30 lg) were resolved elec-
trophoretically in 4–20% acrylamide gel and transferred to
polyvinylidene difluoride membranes (Immobilon-FL,
Millipore, Billerica, MA). After blocking the membranes
with Odyssey blocking buffer, we performed overnight
incubation with rabbit polyclonal antibodies against
BCL-2/adenovirus interacting protein 3 (BNIP3, Cell Sig-
naling, Danvers, MA) and peroxisome proliferator acti-
vated-receptor gamma coactivator 1 alpha (PGC1a, abcam,
Cambridge, MA). Membranes were then incubated for
1 hour with Alexa Fluor 680-conjugated goat anti-rabbit
IgG (Invitrogen, Carlsbad, CA). Membranes were scanned
with Odyssey Infrared Imaging System (LI-COR Bio-
sciences, Lincoln, NE). Band densities were analyzed using
NIH Image J software. Coomassie blue staining was used as
loading control.
Peripheral blood mononuclear cells (PBMCs)
isolation
PBMCs were isolated using Ficoll-PaqueTM gradient. For
this purpose, whole blood (2 mL) was mixed with Hank’s
buffered salt solution (HBSS; 1/1 ratio – volume/volume)
and placed on top of Ficoll-PaqueTM (3 mL) in 15 mL
conical tubes. After centrifuging for 45 min at 500 g, the
layer containing PBMCs (between the plasma and Ficoll-
PaqueTM) was removed. Cells were then washed with
HBSS and centrifuged at 200 g for 10 min. Finally,
PBMCs were resuspended in the appropriate media and
frozen at 80°C until further processing.
Mitochondrial DNA copy number
DNA was extracted using Gentra Puragene extraction
kit according to the manufacturers. Mitochondrial copy
number was calculated by measuring the amount mito-
chondrial DNA relative to the amount of nuclear DNA. To
do so, the mitochondrial encoded NADH dehydrogenase 1
(ND1) gene, the nuclear lipoprotein lipase (LPL) for
PBMCs, and the nuclear B2M gene for skeletal muscle were
amplified using real-time PCR (SYBR green). Fluorescence
signal was detected using a Bio-Rad iCycler. The PCR reac-
tions were performed in triplicate for each gene. Standard
curves of 3, 30, 300, 3,000, and 30,000 nuclear genome
equivalents for each gene were included in each run.
Lactate determination
Plasma lactate levels were measured using a colorimetric/
fluorimetric kit (Biovision, Milpitas, CA) in samples
obtained from arterial blood only.
Isoprostanes and isofurans
Both were measured in plasma separated from EDTA-
anticoagulated blood using negative ion gas-chromatogra-
phy mass spectroscopy (GC/MS) as previously described
(Morrow et al. 1990; Fessel et al. 2002; Milne et al. 2007).
Animal model of mitochondrial dysfunction
Kidneys from mice treated with doxorubicin were
obtained from investigators at Eastern Carolina University
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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following Institutional Animal Care and Use Committee
approval. C57BL/6NJ ovariectomized female mice received
a single IP injection of doxorubicin (20 mg/kg) or vehi-
cle. Seventy-two hours later, kidneys were collected from
animals, snap frozen in liquid nitrogen, and stored at
80°C until further processing. Kidney F2-isoprostanes
and isofurans were measured by GC/MS as previously
described (Morrow et al. 1990; Fessel et al. 2002; Milne
et al. 2007). We also measured complex I activity was
measured in kidney mitochondria. For this purpose,
mitochondria were isolated by differential centrifugation.
Briefly, kidneys were homogenized in a buffer containing
20 mmol/L Tris/MOPS, 400 mmol/L sucrose, and
2 mmol/L EGTA. After initial centrifugation at 750 g,
supernatants were collected and centrifuged at 8,000 g for
10 min. Pellet was then resuspended and centrifuged
again at 8,000 g for 10 min. Crude mitochondria pellet
was then resuspended, protein concentration measured
using BCA method and adjusted to 5 mg/mL of protein.
Complex I activity was detected using a microplate assay
kit (ab109721, abcam, Cambridge, MA) according to the
manufacturer instructions, which measures the oxidation
of NADH to NAD+.
Statistical analysis
Standard graphing and screening techniques were used to
detect any outliers and to ensure data accuracy. The dis-
tributions of continuous endpoints were examined for
normality using Kolmogorov–Smirnov test. In the case of
non-normally distributed data, logarithmic data transfor-
mations were performed or nonparametric tests were
used. General lineal model was used to compare the dif-
ferent groups and contrasts for specific two-group com-
parisons were implemented as appropriate. Age and race
were included as covariates for the analysis of mitochon-
drial volume density in skeletal muscle. Gender, body
mass index (BMI), age and diagnosis of hypertension,
and diagnosis of diabetes were included as covariates in
the rest of the analyses. Additional two-group compar-
isons were also performed using two-sample T-tests or
Wilcoxon rank sum tests. Hypotheses were tested at the
level of a = 0.05. SPSS v22 (IBM, North Carolina) was
used for the analyses.
Results
Ultrastructural abnormalities in skeletal
muscle mitochondria in patients with CKD
stage 5 on MHD
Table 1 shows the demographic characteristic of controls
and patients with CKD stage 5 in the skeletal muscle
biopsy group. Age, body mass index (BMI), gender, mean
arterial blood pressure (MAP), and heart rate were similar
between the groups. There was a greater proportion of
African American in patients with CKD stage 5 than in
controls. We examined the structural changes in skeletal
muscle mitochondria between controls and patients with
CKD stage 5 on MHD. Compared to controls (Fig. 1A),
in patients undergoing MHD we found mitochondria
demonstrating signs of cristae swelling (Fig. 1B), and
double membrane structures compatible with auto-phago-
somes, some of them surrounding mitochondria
(Fig. 1C). These findings suggest that mitophagy, a partic-
ular type of autophagy unique to mitochondria, is
increased in patients with CKD stage 5 on MHD. Intra-
cellular lipofuscin granules (Fig. 1D) were also abundant
in patients undergoing MHD, indicating oxidative dam-
age in mitochondria and lysosomes.
Mitochondrial volume density and
mitochondrial DNA copy number in skeletal
muscle are decreased in patients with CKD
stage 5 on MHD
Mitochondrial volume density, evaluated with stereologi-
cal methods, was significantly lower in patients with CKD
stage 5 compared to controls. There was no effect of race
on mitochondrial volume density and the difference in
mitochondrial volume density between patients with CKD
and controls remained highly significant after adjusting
for race and age (Fig. 2, P = 0.002). Frequency distribu-
tion of mitochondrial volume density in individual myo-
fibers showed a shift to the left in patients undergoing
MHD, indicating a greater proportion of fibers with lower
mitochondrial volume density (Fig. 2). We also found
that mitochondrial volume density decreased as the age
Table 1. Demographic and clinical characteristics: skeletal muscle
biopsy group.
Parameter
Control
(n = 17)
CKD5/MHD
(n = 10) P value
Age (years) 52.9  8.1 50.5  14.3 0.63
Gender (male) 7/17 (41.2%) 7/10 (70%) 0.15
Race (African
American)
3/17 (17.6%) 8/10 (80%) 0.002
Body mass
index (kg/m2)
30.4  6.6 29.1  4.7 0.56
History of diabetes 0/17 (0%) 2/10 (20%) 0.13
MAP (mmHg) 87.2.9  12.4 101.5  23.4 0.12
Heart rate (bpm) 65.7  8.2 73.8  13.2 0.13
Data are presented as mean  SD. MAP, mean arterial blood
pressure.
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increased in the controls (q = 0.65, P = 0.005). There
was no relationship between age and mitochondrial vol-
ume density in patients with CKD stage 5 on MHD. We
also found decreased mitochondrial DNA copy number
in skeletal muscles from patients with CKD stage 5 on
MHD (Fig. 3A). Western blot analysis showed that
BNIP3, an inducer of mitophagy, was elevated in patients
skeletal muscles from patients with CKD stage 5 com-
pared to controls (Fig. 3B). There was no difference in
PGC1a protein expression in skeletal muscles from
patients with CKD stage 5 compared to controls
(P = 0.387).
Mitochondrial DNA copy number in PBMCs
and the stage of CKD
Table 2 shows the demographic characteristic of the three
groups based on the severity of CKD. Of note, subjects
with CKD stage 5 on MHD were younger and had a
higher prevalence of diabetes. Therefore, all the analyses
were adjusted for age and history of diabetes. The per-
centage of African American subjects was also higher in
CKD patients on MHD compared to the small proportion
in the other two groups. Because there were only one or
two African American subjects in these groups we could
not adjust for race. Within subjects with CKD stage 5 on
MHD, race did not affect any of the study outcomes,
however.
We isolated PBMCs from patients at different stages of
CKD in order to evaluate the association between severity
of CKD and mitochondrial DNA copy number. Mito-
chondrial DNA copy number was progressively lower
with increased severity of kidney disease after adjusting
by age, gender, and BMI, as well as presence or absence
of hypertension and history of diabetes (Fig. 4).
Plasma lactate levels and the stage of CKD
Sensitive but not specific to mitochondrial dysfunction,
elevations in plasma lactate are widely used as a marker
of anaerobic metabolism induced by mitochondrial dys-
function. We evaluated plasma lactate levels in the three
groups of subjects. There was no difference in lactate
levels between subjects with non-CKD and CKD stages
A B
C D
Figure 1. Representative electron micrograph of skeletal muscles from a healthy control (A) and patients with CKD stage 5 on maintenance
hemodialysis (CKD 5/MHD). (A) Normal subsarcolemmal mitochondria. (B) Mitochondria with signs of swelling. (C) Double membrane structure
compatible with auto-phagosome. (D) Lipofuscin pigment (scale bar = 500 lm).
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3–4 (Fig. 5). Patients with CKD stage 5 on MHD had
higher lactate levels compared to the other two groups
(Fig. 5, P < 0.001). There was a trend toward inverse cor-
relation between lactate and mitochondrial DNA copy
number that was not statistical significance (P = 0.087)
Isofurans to F2-isoprostanes ratio as a
biomarker of mitochondrial dysfunction
in vivo
F2-isoprostanes and isofurans are both products of
nonenzymatic oxidation of arachidonic acid and have
emerged as highly sensitive and specific measures of
oxidative stress in vivo (Kadiiska et al. 2005). Under con-
ditions of high oxygen tissue tension isofurans are prefer-
entially formed. This may occur due to increased oxygen
delivery (breathing a high FIO2) or due to decreased oxy-
gen consumption (as in mitochondrial dysfunction).
Thus, the ratio of isofurans to F2-isoprostanes have been
proposed as markers of mitochondrial dysfunction (Fessel
et al. 2003). To assess the validity of isofurans formation
as a marker of mitochondrial dysfunction in vivo, we
measured isofurans and F2-isoprostanes in kidneys of
mice treated with doxorubicin, an anthracycline antibiotic
and antineoplastic drug that induces mitochondrial lipid
peroxidation resulting in mitochondrial dysfunction and
oxidative damage. In isolated mitochondria, Complex I
(NADH:ubiquinone oxidoreductase) activity was lower in
kidneys from mice treated with doxorubicin (Fig. 6A,
P = 0.048), confirming the presence of doxorubicin-
Figure 2. (A) Mitochondrial volume density (MVD) in controls with
normal kidney function (N = 17) and patients with CKD stage 5 on
maintenance hemodialysis (CKD 5/MHD, N = 10) in the vastus
lateralis. (B) Frequency distribution of MVD in individual myofibers
showed a greater proportion of fibers with lower MVD in patients
with CKD stage 5.
A
B
C
Figure 3. (A) Mitochondrial DNA (mtDNA) copy number in the
vastus lateralis in controls with normal kidney function (N = 8) and
patients with CKD stage 5 on maintenance hemodialysis (CKD5/
MHD, N = 10). (B) Representative Western blots of BCL-2/
adenovirus interacting protein 3 BNIP3 in the vastus lateralis in
controls and patients with CKD5/MHD (N = 9 in each group);
Coomassie blue staining was used as loading control. (C) Optical
densities were calculated using the NIH software image J.
2016 | Vol. 4 | Iss. 9 | e12780
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induced mitochondrial dysfunction. We found that mice
treated with doxorubicin had similar levels of F2-isopros-
tanes compared with mice treated with vehicle (Fig. 6B).
Isofurans levels tended to be higher in mice treated with
doxorubicin (Fig. 6C, P = 0.08), and the ratio of isofu-
rans to F2-isoprostanes was significantly higher in mice
treated with doxorubicin (Fig. 6D, P = 0.018).
Isofurans and F2-isoprostanes plasma levels
and the stage of CKD in humans
F2-isoprostanes levels were similar among the groups
(Fig. 7A). In contrast, concentrations of isofurans were
higher in patients with CKD stage 5 on MHD compared
with subjects with non-CKD (P = 0.001), but not with
subjects with CKD stages 3–4 (P = 0.2, Fig. 7B). Further-
more, the ratio of isofurans to F2-isoprostanes was
increased in patients with CKD stage 5 suggesting a pref-
erential production of isofurans in patients undergoing
MHD with severe CKD compared to patients with less
severe CKD (Fig. 7C). We further evaluated the correla-
tion between mitochondrial DNA copy number and
markers of oxidative stress. There was no correlation
among these variables in patients with non-CKD or with
CKD stages 3–4. In contrast, the ratio of isofurans to F2-
isprostanes increased as mtDNA decreased in patients
with CKD stage 5 undergoing MHD (q = 0.38,
P = 0.01).
Discussion
This study tested the hypothesis that mitochondrial vol-
ume density in skeletal muscle decreases in patients with
CKD stage 5 on MHD. We found that mitochondrial vol-
ume density and mitochondrial DNA copy number were
decreased; whereas BNIP3, a marker of mitophagy, was
increased in skeletal muscle in patients with CKD stage 5.
Table 2. Demographic and clinical characteristics: CKD severity group.
Parameter
Non-CKD
(n = 109)
CKD 3–4
(n = 36)
CKD 5/MHD
(n = 63) P value
Age (years) 54.6  12.2 60.9  10.9 53.9  12.0 0.01
Gender (male) 76/109 (69.7%) 19/36 (52.8%) 38/63 (59.4%) 0.08
Race (African American) 2/109 (1.8%) 1/36 (2.8%) 41/63 (64.1%) <0.001
Smoker 31/109 (28.4%) 7/36 (19.4%) 20/63 (31.7%) 0.4
Body mass index (kg/m2) 29.9  7.7 30.3  5.8 30.6  8.2 0.8
History of hypertension 87/109 (80.6%) 33/36 (91.7%) 55/63 (87.3%) 0.2
History of diabetes 29/109 (26.6%) 15/36 (41.7%) 33//63 (52.4%) 0.001
Systolic blood pressure (mmHg) 125.3  18.9 125.6  17.7 149.2  25.3 (pre)
127.4  18.6 (post)
<0.001
0.8
Data are presented as mean  SD. Pre indicates predialysis and post indicates postdialysis.
Figure 4. Mitochondrial DNA (mtDNA) copy number in peripheral
blood mononuclear cells (PBMCs) in patients with different stages
of CKD. Patients were divided into three groups according to eGFR:
Non-CKD (eGFR > 60 mL/min, N = 28), CKD 3–4 (eGFR between
15 and 60 mL/min, N = 17), and CKD 5/MHD (eGFR < 15 mL/min
on maintenance hemodialysis, N = 42). P values were adjusted for
gender, age, BMI, and history of diabetes.
Figure 5. Plasma lactate levels in patients with different stages of
chronic kidney disease (CKD). Patients were divided in three groups
according to eGFR: Non-CKD (eGFR > 60 mL/min, N = 109), CKD
3–4 (eGFR between 15 and 60 mL/min, N = 35), and CKD 5/MHD
(eGFR < 15 mL/min on maintenance hemodialysis, N = 42). P
values were adjusted for gender, age, BMI, and history of diabetes.
Normal lactate concentrations are less than 2 mmol/L.
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We also found significant structural abnormalities in
skeletal muscle mitochondria compared to individuals
with normal kidney function. This study also tested the
hypothesis that circulating biomarkers of mitochondrial
dysfunction and oxidative stress increase with the severity
of chronic kidney disease. We found that mitochondrial
dysfunction, measured by mtDNA copy number, lactate,
or isofurans concentration, is present and worse in
patients with CKD stage 5 undergoing MHD compared
to patients with non-CKD and with earlier stages of CKD
(i.e., stages 3 and 4). In addition, mtDNA copy number
is decreased even in patients with CKD stage 3–4, suggest-
ing that changes in mitochondrial DNA occur before the
establishment of end-stage renal disease. Finally, our
results also indicate that plasma isofurans concentration
and the ratio of isofurans to F2-isoprostanes are potential
biomarkers of mitochondrial dysfunction in vivo.
This is the first study to demonstrate decreased mito-
chondrial volume density in skeletal muscle in patients
undergoing MHD. We also found that mitochondrial
DNA copy number is decreased in the muscles of patients
undergoing MHD. These observations are consistent with
previous studies that showed reduced mitochondrial
oxidative capacity and reduced activity of mitochondrial
enzymes in skeletal muscle from patients with end-stage
renal disease (Adey et al. 2000; Lewis et al. 2012). A pos-
sible explanation for these findings is the increased mito-
phagy as indicated by increased BNIP3 content in skeletal
muscles from patients on MHD. BNIP3 is a BH3-only
protein that is translocated to the outer mitochondrial
membrane and induces mitophagy (Zhang et al. 2008),
the cellular process that removes damaged mitochondria.
Previous studies also showed changes in mitochondria
morphology, myofibrillar degeneration, autophagic vac-
uoles, lipofuscin granules, and intracellular accumulation
of glycogen and lipid (Ahonen 1980; Shah et al. 1983;
Diesel et al. 1993; Lewis et al. 2012). We confirmed the
presence of these abnormalities, particularly swollen mito-
chondria and autophagosomes, and lipofuscin pigments.
The latter has been linked to decreased lysosomal func-
tion and is commonly present with aging (Terman et al.
2006, 2009; O’Leary et al. 2013). Thus, the skeletal muscle
ultrastructure shows signs of accelerated aging in patient
with CKD stage 5. Overall, the mitochondrial structural
abnormalities could be one of the reasons leading to
diminished physical performance and endurance observed
in patients with CKD. It may also explain the increased
prevalence of frailty and sarcopenia in this population.
The etiology of these abnormalities is not clear, but a
study in an animal model of CKD suggests that reduction
in muscle mitochondria precedes the loss of muscle vol-
ume and muscle power (Tamaki et al. 2014). We found
that skeletal muscle mitochondrial number is decreased in
patients with CKD stage 5; however, further studies
should evaluate if muscle mitochondrial reduction pre-
cedes the onset of sarcopenia in patients with CKD.
A previous study reported that mtDNA copy number
in PBMCs is lower in patients on MHD than in healthy
controls in individuals aged 50 years or older, and that
mtDNA copy number in PBMCs predicts survival in
A B
C D
Figure 6. Mitochondrial complex I activity, F2-isoprostanes, and isofurans in kidneys from mice treated with doxorubicin. Mice were treated
with a single IP injection of either vehicle (N = 10) or doxorubicin (20 mg/kg, N = 10). Kidneys were collected 72 h later. Complex I activity was
normalized to the amount of protein in mitochondria pellets.
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patients with end-stage renal disease undergoing MHD
(Rao et al. 2009). We also found that mitochondrial
DNA copy number in PBMCs is decreased in patients on
MHD compared to controls with no CKD. Our study fur-
ther suggests that mtDNA copy number in PBMCs is
already decreased in patients with CKD stages 3–4. Mito-
chondrial DNA is more susceptible to damage by oxida-
tive stress than nuclear DNA because of a lack of
protection from histone proteins (Croteau and Bohr
1997). Mutations in mtDNA and reduced mtDNA copy
number are commonly present in cells exposed to exces-
sive concentration of reactive oxygen species (Fliss et al.
2000). Thus, mtDNA copy number has been proposed as
a surrogate of mitochondrial function (Malik and Czajka
2013).
Lactate concentration reflects anaerobic metabolism,
and is a crude measurement of mitochondrial dysfunction
from low mitochondrial oxidative capacity. Resting lactate
levels are high in obese individuals and correlate posi-
tively with blood pressure and insulin resistance (DiGiro-
lamo et al. 1992; Baron et al. 1993; Crawford et al. 2008).
A recent community-based cohort study found that
increased lactate levels were associated with higher risk of
heart failure and all-cause mortality (Matsushita et al.
2013). Interestingly, we found that lactate levels are higher
in patients with CKD stage 5 on MHD, a population with
high mortality rates and an increased incidence of heart
failure. A previous study found that, in patients undergo-
ing MHD, lactate levels correlate inversely with mitochon-
drial DNA copy number in PBMCs, suggesting the
association between mitochondrial dysfunction and lactate
levels (Rao et al. 2009). We also noted a trend toward an
inverse association between lactate and mitochondrial
DNA copy number but did not reach statistical signifi-
cance. Nevertheless, more studies are required to study
the relationship between mitochondrial dysfunction and
lactate in patients on MHD.
The relative formation of either F2-isoprostanes or iso-
furans depends on tissue oxygen tension. In conditions of
high oxygen tension the formation of isofurans is favored
(Fessel et al. 2002). This may occur due to decreased oxy-
gen consumption (as occurs in mitochondrial dysfunc-
tion). We found that the levels of isofurans were higher
in patients with CKD stage 5 on MHD than in patients
with CKD stages 1–4. Furthermore, the increased ratio of
isofurans to F2-isoprostanes suggests a preferential pro-
duction of isofurans in patients undergoing MHD. These
findings may be a consequence of mitochondrial dysfunc-
tion, as previously hypothesized (Fessel et al. 2003). We
tested this hypothesis in mice injected with doxorubicin,
which is known to induce mitochondrial dysfunction
(Berthiaume and Wallace 2007). Doxorubicin is an anti-
neoplastic agent that interacts with the mitochondrial
NADH dehydrogenase (complex I) forming a semiqui-
none radical (Berthiaume and Wallace 2007). Doxoru-
bicin inhibits mitochondrial respiration and complex I
activity (Yen et al. 1999; Gilliam et al. 2013). In accor-
dance, we found that complex I activity is decreased in
kidney mitochondria from mice treated with doxorubicin.
We also found that kidney isofurans to F2-isoprostanes
ratios are increased in mice treated with doxorubicin,
showing that doxorubicin-induced mitochondrial dys-
function is associated with increased isofurans formation.
A
B
C
Figure 7. F2-isoprostanes and isofurans in patients with different
stages of chronic kidney disease (CKD). Patients were divided in
three groups according to eGFR: Non-CKD (eGFR > 60 mL/min,
N = 74), CKD 3–4 (eGFR between 15 and 60 mL/min, N = 26), and
CKD5/MHD (eGFR < 15 mL/min on maintenance hemodialysis,
N = 61). P values were adjusted for gender, age, BMI, and history
of diabetes. Normal values in healthy controls for F2-isoprostanes
and isofurans are 35  6 pg/mL and 43  5 pg/mL, respectively.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Furthermore, we also found that the ratio of isofurans to
F2-isoprostanes correlates inversely with mitochondrial
DNA copy number in patient on CKD stage 5. This find-
ing suggests that the increased ratio reflect oxidative stress
due to mitochondrial dysfunction in patients on MHD.
Moreover, a recent dose-escalation study found that sup-
plementation with coenzyme Q10, which may improve
mitochondrial function, decreased isofurans levels and the
ratio of isofurans to F2-isoprostanes in patients on MHD
(Yeung et al. 2015). Further studies are required, how-
ever, to establish the specific sources of the overall oxida-
tive stress burden in patients on MHD.
This study has some limitations. We did not evaluate
mitochondrial function in skeletal muscle; however, due to
the organization of mitochondrial cristae, mitochondrial
ultrastructure correlates with mitochondrial function (Zick
et al. 2009). Further studies should confirm the association
between mitochondrial ultrastructure and function in
skeletal muscle in patients with CKD. The study groups
were not matched by race. Nevertheless, race did not affect
any of the study outcomes in patients with CKD stage 5 on
MHD. Furthermore, a previous study did not find associa-
tion between race and mitochondrial DNA copy number in
a cohort of patients with CKD stage 5 (Rao et al. 2009).
Predialysis blood pressure was also significantly higher in
patients with CKD stage 5 compared to non-CKD and
patients with CKD stage 3–4. Although we cannot exclude
a confounding effect of hypertension, in a subgroup of
patients that were matched by age, gender, race, and BMI,
we found increased mtDNA copy number in hypertensive
subjects without CKD compared to patients with CKD
stage 5 (data not shown). Furthermore, we found no corre-
lation between blood pressure and mtDNA copy number
in each of the studied groups. These results suggest that ele-
vated blood pressure does not affect mtDNA copy number.
In contrast, the inclusion of controls with a high prevalence
of cardiovascular disease, comparable to patients with CKD
stage 5, may be considered as strength to avoid overestima-
tion of the differences among the groups.
In summary, we found that patients with CKD stage 5
have decreased mitochondrial volume density in skeletal
muscle than non-CKD controls that may be explained by
increased mitophagy. We also observed numerous ultra-
structural abnormalities in muscles biopsies from patients
with CKD stage 5 on MHD such as swollen mitochon-
dria, liposfuscin pigments, and autophagosomes. We
found that mitochondrial oxidative stress and dysfunc-
tion, assessed by in vivo biomarkers (i.e., mitochondrial
DNA copy number in PBMCs, plasma lactate, and ratio
of isofurans to F2-isoprostanes), is increased in patients
with CKD stage 5 on MHD compared to patients on
CKD stage 3–4. Mitochondrial DNA copy number may
be a more sensitive marker of mitochondrial function
since it is already decreased by CKD stage 3–4. Our data
in an animal model indicate that doxorubicin-induced
mitochondrial dysfunction is associated with increase in
renal isofurans concentrations and an increase in the ratio
of isofurans to F2-isoprostanes suggesting that measure-
ment of this ratio can be used to detect mitochondrial
dysfunction in vivo. Additional studies are needed to vali-
date the potential utility of novel in vivo biomarkers of
mitochondrial dysfunction in CKD and interventions tar-
geted at these abnormalities.
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